SkinBioTherapeutics PLC (SBTX) — Strategic Asset Allocation Index
SkinBioTherapeutics PLC (SBTX) has a Strategic Asset Allocation Index of 9.1% as of December 2022. Strategic assets (PP&E of GBX110.70K plus long-term investments of GBX-) total GBX110.70K, measured against net assets of GBX1.21 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See SkinBioTherapeutics PLC balance sheet quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
SkinBioTherapeutics PLC Strategic Asset Allocation Index (2019–2022)
This chart shows how SkinBioTherapeutics PLC's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of December 2022, the index stands at 9.1%, representing strategic assets of GBX110.70K against net assets of GBX1.21 Million GBX. For live market cap and overall valuation, see SBTX stock market capitalisation.
Annual Strategic Asset Allocation Index for SkinBioTherapeutics PLC (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for SkinBioTherapeutics PLC from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See SBTX net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (GBX) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 5.1% | GBX126.90K | GBX126.90K | GBX- | GBX2.48 Million | ▲ +2.4 pp |
| 2021 | 2.7% | GBX143.33K | GBX143.33K | GBX- | GBX5.22 Million | ▲ +2.7 pp |
| 2020 | 0.1% | GBX1.70K | GBX1.70K | GBX- | GBX2.47 Million | ▼ -0.1 pp |
| 2019 | 0.2% | GBX6.80K | GBX6.80K | GBX- | GBX3.81 Million | — |